Patents by Inventor PAUL ALFRED SMITH

PAUL ALFRED SMITH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
    Patent number: 11466324
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: October 11, 2022
    Assignee: UCB BIOPHARMA SRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Fairfull Watt
  • Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
    Patent number: 10537566
    Abstract: The present invention relates to combinations and pharmaceutical compositions comprising siponimod and laquinimod, and the use of said combinations and/or compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.
    Type: Grant
    Filed: October 14, 2015
    Date of Patent: January 21, 2020
    Assignee: Novartis AG
    Inventor: Paul Alfred Smith
  • LIPOCALIN 2 AS A BIOMARKER FOR IL-17 INHIBITOR THERAPY EFFICACY
    Publication number: 20190144945
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Application
    Filed: January 15, 2019
    Publication date: May 16, 2019
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, John Leigh Rundle, Paul Alfred Smith, Gillian Fairfull Watt
  • Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
    Patent number: 10208349
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Grant
    Filed: November 19, 2013
    Date of Patent: February 19, 2019
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Adam Samuel Platt, Stephen Edward Rapecki, Mara Fortunato, David Robert Rainey, Jon Leigh Rundle, Paul Alfred Smith, Gillian Sairfull Watt
  • COMBINATIONS COMPRISING SIPONIMOD AND LAQUINIMOD FOR THE TREATMENT OF MULTIPLE SCLEROSIS
    Publication number: 20170304289
    Abstract: The present invention relates to combinations and pharmaceutical compositions comprising siponimod and laquinimod, and the use of said combinations and/or compositions for the treatment of multiple sclerosis, particularly secondary progressive multiple sclerosis.
    Type: Application
    Filed: October 14, 2015
    Publication date: October 26, 2017
    Applicant: NOVARTIS AG
    Inventor: Paul Alfred Smith
  • LIPOCALIN 2 AS A BIOMARKER FOR IL-17 INHIBITOR THERAPY EFFICACY
    Publication number: 20140080134
    Abstract: The present invention provides the use of lipocalin 2 (LCN2) as a biomarker for IL-17 mediated diseases and for monitoring the response of a patient to anti-IL-17 therapy.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: UCB PHARMA S.A.
    Inventors: ADAM SAMUEL PLATT, STEPHEN EDWARD RAPECKI, MARA FORTUNATO, DAVID ROBERT RAINEY, JON LEIGH RUNDLE, PAUL ALFRED SMITH, GILLIAN SAIRFULL WATT